Waksal's Kadmon rapidly builds on hepatitis C franchise with Valeant deals
This article was originally published in Scrip
Kadmon Pharmaceuticals, Samuel Waksal's new venture, is moving quickly to strengthen its hepatitis C franchise.
You may also be interested in...
Initial public offering activity has been slow as the summer kicks into high gear, but a filing with SEC by Kadmon has peculiarities that promise high drama the likes of which only Sam Waksal could offer.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.